ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2007. Net revenues for the fourth quarter of 2007 increased 32% to $105.0 million from $79.5 million in the fourth quarter of 2006. Diluted earnings per share (EPS) for the fourth quarter of 2007 (before restructuring and Sular inventory related charges of $0.21) increased 37% to $0.52 compared with $0.38 in the fourth quarter of 2006. Diluted earnings per share for the fourth quarter 2007, including the restructuring charges, were $0.31 per share.
